You are currently viewing the editor's summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
Register for free to read this article
As a service to the community, this article is available for free. Existing users log in.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
ACT against multiple myeloma
Adoptive T cell therapy (ACT) has had some success in treating certain types of cancer; however, widespread use is limited in part by the lack of tumor-specific targets. Tumor-infiltrating T cells may overcome this limitation for solid tumors. Noonan et al. now show in a phase 1 clinical trial that bone marrow can be a source of ACT for hematologic malignancies such as multiple myeloma. Marrow-infiltrating lymphocytes (MILs) demonstrated myeloma-specific immunity in the bone marrow up to 1 year after ACT, and a significant increase was observed in progression-free survival. If these results can be replicated in larger studies, MILs may represent a source for ACT for hematologic malignancies and bone marrow–infiltrating solid tumors.
- Copyright © 2015, American Association for the Advancement of Science
